在淋巴结受累的黑色素瘤手术前测试 Encorafenib 和 Binimetinib 的治疗效果
Encorafenib 联合 Binimetinib 治疗皮肤或未知原发性黑色素瘤可切除局部转移患者的 II 期新辅助研究(III 期 N1B/C/D)
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.
研究概览
地位
条件
详细说明
PRIMARY CLINICAL OBJECTIVE:
I. To evaluate the pathologic complete response (pCR) rate of neoadjuvant treatment with encorafenib and binimetinib.
SECONDARY CLINICAL OBJECTIVES:
I. To determine response rate (RR) (Response Evaluation Criteria in Solid Tumors [RECIST]), disease-free survival (DFS) and overall survival (OS).
II. To describe correlation of pCR with RR, DFS and OS. III. To assess safety and toxicity.
CORRELATIVE SCIENCE OBJECTIVES:
I. To evaluate CD8 positive (+) T cell infiltration and Ki-67 status in tumor or tumor bed pre, during, and post neoadjuvant treatment and the change in CD8+ tumor infiltrating lymphocyte (TIL) with neoadjuvant treatment and correlate with clinical response.
II. To compare local review for pathologic response with central pathology review.
III. To assess the correlation between change in fluorothymidine F-18 (18F-FLT) PET/CT uptake and change in Ki-67.
IMAGING OBJECTIVES:
I. To compare the change in 18F-FLT PET/CT uptake (from baseline to post-neoadjuvant therapy) among patients with and without pathologic complete response.
II. To compare post-neoadjuvant 18F-FLT PET/CT uptake among patients with and without pathologic complete response.
III. To estimate an optimal threshold for prediction of pathologic complete response using i) change in 18F-FLT PET/CT uptake, and ii) post-neoadjuvant 18F-FLT PET/CT uptake.
IV. To assess the correlation between change in 18F-FLT PET/CT uptake and change in Ki-67.
OUTLINE:
NEOADJUVANT TREATMENT: Patients receive 18F-FLT intravenously (IV) and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later.
SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery.
ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 3 years.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、美国、90033
- Los Angeles County-USC Medical Center
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
City of Saint Peters、Missouri、美国、63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur、Missouri、美国、63141
- Siteman Cancer Center at West County Hospital
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
St Louis、Missouri、美国、63129
- Siteman Cancer Center-South County
-
St Louis、Missouri、美国、63136
- Siteman Cancer Center at Christian Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19111
- Fox Chase Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Carbone Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient must have histologically proven melanoma that is clinically evident (macroscopic lymphadenectomy [LAD]) stage III B/C/D, (American Joint Committee on Cancer [AJCC] 8th edition) of cutaneous origin or unknown primary. Patients must have at least one clinically evident lymph node metastasis (N1c patients are not eligible).
-
This may be an initial presentation with primary tumor and nodal metastases or locoregional nodal relapse with history of resected primary melanoma
-
Stage IIIB
- T0-3a N1b M0
- T1a-3a N2b M0
-
Stage IIIC
- T0 or T3b-4b N2b M0
- T3b-4b N1b M0
- Any T N2c M0 (at least 1 clinically evident node)
- T0-4a N3b M0
-
Stage IIID
- T4b N3b/c M0 (if 3c: at least 1 clinically evident node)
-
-
Patient must have measurable disease on baseline imaging scans, obtained within 4 weeks prior to registration as defined by RECIST and by the following criteria
-
The melanoma target tumor must be completely resectable as determined by a surgical oncologist or experienced melanoma surgeon
- Extensive satellitosis or in transit metastases are not considered completely resectable
-
-
Patient must have BRAF V600 mutation positive based on report from Clinical Laboratory Improvement Act (CLIA) certified laboratory
-
Patient must be medically fit to undergo surgery
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained < 14 days prior to registration)
-
Hemoglobin >= 8 g/dL without transfusion (obtained < 14 days prior to registration)
-
Platelets >= 100 x 10^9/L without transfusion (obtained < 14 days prior to registration)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.0 x upper limit of normal (ULN) (obtained < 14 days prior to registration)
-
Total bilirubin =< 1.5 x ULN and < 2 mg/dL; OR total bilirubin > 1.5 x ULN with indirect bilirubin < 1.5 x ULN (obtained < 14 days prior to registration)
-
Serum creatinine =< 1.5 x ULN, or calculated creatinine clearance > 50 mL/min by Cockcroft-Gault formula (obtained < 14 days prior to registration)
-
Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 x ULN (obtained < 14 days prior to registration)
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Patient must be able to take oral medications
-
Patient must be able to lie still during the 18F-FLT PET/CT scan for the duration of the imaging study (up to 1.5 hours), have no previous indication of allergic reaction to the radiotracer, and meet the size limits of the qualified PET/CT scanner
-
Patient must be participating in this study at an institution which has completed the ECOG-American College of Radiology Imaging Network (ACRIN) defined PET/CT scanner qualification procedures and received ECOG-ACRIN PET scanner approval
-
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and stable and adequate CD4 counts (>= 500 mm^3) on screening labs provided they meet all other protocol criteria for participation and that there is no high risk drug interactions
-
Women of childbearing potential and sexually active males must use accepted and effective method(s) of contraception or to abstain from sexual intercourse for the duration of their participation in the study and for at least 30 days after the last dose of protocol treatment for female patients, and for at least 90 days after the last dose of protocol treatment for male patients. In addition, female patients must not donate ova from the time of registration until 30 days after the last dose of study treatment. Male patients must not donate sperm from the time of registration until 90 days after the last dose of protocol treatment
-
Patient may be on anticoagulation at prophylactic or therapeutic levels. Patients must not be using anticoagulants at therapeutic levels that may interfere with encorafenib and binimetinib
Exclusion Criteria:
-
Stage IV melanoma
-
Patient must not have any prior treatment with BRAF inhibitor (BRAFi) or MEK inhibitor (MEKi)
-
Patient must not have any evidence of distant metastases
-
Patient must not have any prior adjuvant therapy at this disease presentation; prior immune therapy (such as adjuvant interferon or checkpoint inhibitors) is permitted if >= 6 months from last treatment
-
Patient must not have any prior radiation to the site of evaluable disease
-
Patient must not have active infection requiring treatment with parenteral antibiotics
-
Patient must not have active hepatitis B, and/or active hepatitis C infection given concerns for drug interactions or increased toxicities. Testing is not required
-
Patient must not have other significant medical, surgical, or psychiatric conditions that in the opinion of the investigator may interfere with compliance, make the administration of study medications hazardous
-
Patient must not have had previous or concurrent other malignancy with the following exceptions:
- Adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix
- Other solid tumor: if treated and without evidence of recurrence for at least 2 years prior to study entry
-
Women must not be pregnant or breast-feeding due to potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the systemic antineoplastic medications, as well as surgery and radiation being used. Patients must also not expect to conceive or father children from the time of registration, while on study, treatment, and until at least 30 days after the last dose of study treatment (for female patients) and 90 days after the last dose of study treatment (for male patients). All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not have known hypersensitivity or contraindication to any component of binimetinib or encorafenib or their excipients
-
Patient must not have impaired cardiovascular function or clinically significant cardiovascular disease including, but not limited to, any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) < 6 months prior to registration
- Congestive heart failure requiring treatment (New York Heart Association grade >= 2)
- Left ventricular ejection fraction (LVEF) < 50% as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO)
- Uncontrolled hypertension defined as persistent systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite current therapy
- History or presence of clinically significant cardiac arrhythmias (including resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia)
- Baseline corrected QT (QTc) interval >= 480 ms
-
Patient must not have impairment of gastrointestinal function or disease which may significantly alter the absorption of study drug (e.g., active ulcerative disease, uncontrolled vomiting or diarrhea, malabsorption syndrome, small bowel resection with decreased intestinal absorption), or recent (=< 3 months) history of a partial or complete bowel obstruction, or other conditions that will interfere significantly with the absorption of oral drugs
-
Patient must not have any known history of acute or chronic pancreatitis
-
Patient must not have any concurrent neuromuscular disorder that is associated with elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy
-
Patient must not have any known history or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, factor V Leiden or activated protein C resistance); history of retinal degenerative disease
-
Patient must not use any medication (including herbal medications, supplements, or foods), or use of a prohibited medication =< 1 week prior to registration
-
Patient must not have a history of thromboembolic or cerebrovascular events =< 12 weeks prior to registration. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli
- NOTE: Patients with thromboembolic events related to indwelling catheters or other procedures may be registered
- NOTE: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to register as long as they are on a stable dose of anticoagulants for at least 4 weeks
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Neoadjuvant encorafenib + binimetinib, surgery, adjuvant encorafenib + binimetinib
NEOADJUVANT TREATMENT: Patients receive 18F-FLT IV and undergo a PET/CT scan approximately 60 minutes later. Within 2 weeks, patients receive encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive 18F-FLT IV and undergo a second PET/CT scan approximately 60 minutes later. SURGICAL RESECTION: Within 2 weeks of completing therapy with encorafenib and binimetinib, patients undergo surgery. ADJUVANT TREATMENT: Within 2-7 days after surgery, patients resume treatment with encorafenib PO QD and binimetinib PO BID on days 1-28. Treatment repeats every 28 days for up to 11 cycles in the absence of disease progression or unacceptable toxicity. |
Undergo surgery Given PO
其他名称:
Given PO
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pathologic Complete Response
大体时间:Assessed at 10-12 weeks
|
Pathologic complete response (pCR) is defined as complete absence of viable tumor in the treated tumor bed. Partial pathologic response (pPR) is defined as less than or equal to 50% of the treated tumor bed is occupied by viable tumor cells. Pathologic non-response is defined as great than 50% of the treated tumor bed is occupied by viable tumor cells. |
Assessed at 10-12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response
大体时间:Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years
|
Objective response is defined as either complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Complete response is defined as disappearance of all lesions. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters and/or persistence of one or more non-target lesion(s). Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years
|
|
Disease-free Survival
大体时间:Assessed at baseline, 8 weeks, then every 12 weeks up to 19.4 months
|
Disease-free survival is defined as the time from date of surgical resection to the date of recurrence or death, whichever occurs first. Recurrence must be documented by radiologic exams and with biopsy in all cases except for brain metastases (biopsy not required). Abnormal blood studies alone (e.g., elevated transaminases or alkaline phosphatase) are not sufficient evidence of relapse. Whenever possible, histologic proof of recurrence should be obtained unless the lesion is not accessible or a biopsy would cause undue risk to the patient. |
Assessed at baseline, 8 weeks, then every 12 weeks up to 19.4 months
|
|
Overall Survival
大体时间:Assessed at every 3 months for 2 years and then every 6 months, up to 2 years 9 months
|
Overall survival is defined as the time from registration to death or date last known alive, which is the censoring date for patients who are still alive. |
Assessed at every 3 months for 2 years and then every 6 months, up to 2 years 9 months
|
|
Associations Between pCR and Best Response
大体时间:Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years
|
Association between pCR and best response will be reported. |
Assessed at baseline, 8 weeks, then every 12 weeks up to 1.4 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
CD8+ T Cell Infiltration and Ki-67 Status
大体时间:Assessed at baseline, during neoadjuvant treatment and at surgery
|
Evaluation of CD8+ T cell infiltration and Ki-67 status in tumor or tumor bed pre, during, and post neoadjuvant treatment will be performed. The change in CD8+ TIL with neoadjuvant treatment will also be evaluated. |
Assessed at baseline, during neoadjuvant treatment and at surgery
|
|
Concordance Between Local Review for Pathologic Response and Central Pathology Review
大体时间:Assessed at surgery
|
The concordance between local review for pathologic response and central pathology review will be performed. |
Assessed at surgery
|
|
Change in 18F-FLT PET/CT Uptake
大体时间:Assessed at baseline and post-neoadjuvant therapy
|
Comparison of the change in 18F-FLT PET/CT uptake from baseline to post-neoadjuvant therapy between patients with and without pathologic complete response will be performed. |
Assessed at baseline and post-neoadjuvant therapy
|
|
18F-FLT PET/CT Uptake
大体时间:Assessed after neoadjuvant treatment, about 16 weeks
|
The uptake value of 18F-FLT PET/CT will be evaluated after neoadjuvant treatment is completed. This value will be compared between patients with and without pathologic complete response. |
Assessed after neoadjuvant treatment, about 16 weeks
|
|
Association Between Pathologic Complete Response and Change in 18F-FLT PET/CT Uptake as Well as Post-neoadjuvant 18F-FLT PET/CT Uptake
大体时间:Assessed at baseline and post-neoadjuvant treatment
|
The association between pathologic complete response and change in 18F-FLT PET/CT uptake as well as post-neoadjuvant 18F-FLT PET/CT uptake will be evaluated. An optimal threshold of 18F-FLT PET/CT uptake for prediction of pathologic complete response will be estimated. |
Assessed at baseline and post-neoadjuvant treatment
|
|
Correlation Between Change in 18F-FLT PET/CT Uptake and Change in Ki-67
大体时间:Assessed at baseline and post-neoadjuvant treatment
|
The correlation between change in 18F-FLT PET/CT uptake and change in Ki-67 will be evaluated. |
Assessed at baseline and post-neoadjuvant treatment
|
合作者和调查者
调查人员
- 首席研究员:Leslie A Fecher、ECOG-ACRIN Cancer Research Group
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- EA6183
- U10CA180820 (美国 NIH 拨款/合同)
- EA6183 (其他标识符:CTEP)
- NCI-2019-07407 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- EA6183 (其他标识符:ECOG-ACRIN Cancer Research Group)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.